MarketPR
Twenty-six companies account for 90% of the United States pharmaceutical market, according to Donald Trump.
The figure places domestic drug supply capacity within a narrow set of producers and raises direct questions about where throughput and order-book concentration actually sit across the sector.
Trump offered no breakdown by company name, product segment, or revenue share alongside the claim.
A market where 26 entities carry nine-tenths of output implies a long tail of smaller producers holds the remaining share, though Trump did not characterize that segment or its role in overall capacity.
Keep reading